e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aytu BioPharma, Inc. - Common Stock
(NQ:
AYTU
)
2.660
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aytu BioPharma, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTC – AAVVF), Canaccord Genuity Group Inc. (OTC – CCORF)
November 17, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
AYTU Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Aytu Biopharma, Inc.
November 17, 2026
From
Ademi LLP
Via
GlobeNewswire
AYTU Stock Alert: Halper Sadeh LLC is Investigating Whether Aytu BioPharma, Inc. is Obtaining a Fair Price for its Shareholders
November 16, 2026
From
Halper Sadeh LLC
Via
Business Wire
Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results
November 16, 2026
Due to the pending merger with Rosemont Pharmaceuticals Holdings, Inc., the Company will not be holding an earnings conference call to discuss its financial results
From
Aytu BioPharma, Inc.
Via
ACCESS Newswire
Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion
November 16, 2026
From
Rosemont Pharmaceuticals
Via
GlobeNewswire
Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
November 16, 2026
Agreement with Rosemont Pharmaceuticals provides for all-cash consideration of $2.70 per share Tender offer price represents 41.1% premium to 30-day volume-weighted average price and 51.7% premium to...
From
Aytu BioPharma, Inc.
Via
ACCESS Newswire
Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026
November 10, 2026
From
Aytu BioPharma, Inc.
Via
ACCESS Newswire
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
September 22, 2026
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 million EXXUA net revenue of $6.6...
From
Aytu BioPharma, Inc.
Via
ACCESS Newswire
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
September 16, 2026
From
Aytu BioPharma, Inc.
Via
ACCESS Newswire
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
June 01, 2026
Via
ACCESS Newswire
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 18, 2026
Via
ACCESS Newswire
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
May 13, 2026
Via
ACCESS Newswire
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
May 06, 2026
Via
ACCESS Newswire
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
February 03, 2026
Via
ACCESS Newswire
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
January 20, 2026
Via
ACCESS Newswire
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
January 20, 2026
Via
ACCESS Newswire
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
January 13, 2026
Via
ACCESS Newswire
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
January 12, 2026
Via
ACCESS Newswire
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
December 18, 2025
Via
ACCESS Newswire
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
December 15, 2025
Via
ACCESS Newswire
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
November 24, 2025
Via
ACCESS Newswire
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
November 13, 2025
Via
ACCESS Newswire
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
November 05, 2025
Via
ACCESS Newswire
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
October 28, 2025
Via
ACCESS Newswire
Aytu BioPharma to Present at Upcoming October 2025 Conferences
October 10, 2025
Via
ACCESS Newswire
11 Company Presentations Today at The MicroCap Rodeo Conference
September 25, 2025
Via
ACCESS Newswire
Aytu BioPharma to Present at Upcoming September 2025 Conferences
September 24, 2025
Via
ACCESS Newswire
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
September 23, 2025
Via
ACCESS Newswire
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
September 16, 2025
Via
ACCESS Newswire
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
June 25, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.